22.6 C
New York
Saturday, June 13, 2026

Tag: pathways

newssourceFORcompanyinformationcontent1marketreleases

Viewpoint with Dennis Quaid and DeKalb Convention & Visitors Bureau Present: Your Passport to a World of Culture

LOS ANGELES, Aug. 4, 2025 /PRNewswire/ -- Viewers can prepare to have their perceptions broadened in an upcoming segment of "Viewpoint with Dennis Quaid,"...

Video Explores How Elon Musk’s Starlink Could Reshape Everyday Life Ahead of Predicted August 13 Announcement

Baltimore, MD, Aug. 01, 2025 (GLOBE NEWSWIRE) -- A released briefing featuring entrepreneur James Altucher examines the human impact of Elon Musk’s Starlink technology and how it could permanently alter communications, commerce, and access to information worldwide.

NeuroSense Provides Business Update and Progress for the First Half of 2025

CAMBRIDGE, Mass., July 31, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today provided...

Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson’s Disease

The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of the investigational...

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced second quarter 2025 financial results and provided a corporate update.

Energy Transition Meets Emerging Tech on August 20th at EnerCom’s 30th Anniversary Energy Investment Conference

Landmark 30th Anniversary EnerCom Denver – The Energy Investment Conference Announces Energy Transition and Emerging Technology Session Schedule Qualified Investors and Analysts Can Register at...

CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results

Viridian Metals Outlines Basin-Scale Copper Targets and Structural Controls at Sedna and Results of AGSM

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ VANCOUVER, BC, July 31, 2025 /CNW/ - Viridian Metals Inc....

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

Top judicial officials: State supreme courts must lead innovation & reform of legal education and admissions

WILLIAMSBURG, Va., July 30, 2025 /PRNewswire/ -- The Conference of Chief Justices (CCJ) and Conference of State Court Administrators (COSCA) today released the findings of...

New Trail, New Moves: Sheridan College Just Got More Connected

BRAMPTON, ON, July 30, 2025 /CNW/ - Sheridan College is enhancing safety and accessibility of active transportation infrastructure on campus with the support of...

Sumitomo Pharma America Announces that the European Medicines Agency Has Granted Orphan Drug Designation to Nuvisertib (TP-3654) for the Treatment of Myelofibrosis

– Nuvisertib (TP-3654), an oral investigational highly selective PIM-1 kinase inhibitor, is being evaluated in patients with relapsed or refractory myelofibrosis (MF) – MARLBOROUGH, Mass.,...

EuMentis Therapeutics Receives U.S. FDA Clearance of IND Application for EM-221, a Novel PDE10A Inhibitor for Schizophrenia

-Company expects to initiate Phase 2 study in 2H 2025- SAN DIEGO, July 30, 2025 /PRNewswire/ -- EuMentis Therapeutics, Inc., ("EuMentis"), a clinical-stage drug development company...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPathways

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers